Surgical treatment of breast carcinoma after neoadjuvant therapy
Authors:
V. Petrů 1; P. Vážan 2; M. Zábojníková 3; J. Duben 1; B. Dudešek 1; P. Kosáč 1; M. Ratajský 1; P. Jančík 1; J. Gatěk 1,4
Authors‘ workplace:
Chirurgické oddělení EUC Zlín
1; CGB laboratoř patologie Zlín
2; Onkologie KNTB Zlín
3; Univerzita Tomáše Bati ve Zlíně
4
Published in:
Rozhl. Chir., 2020, roč. 99, č. 4, s. 172-178.
Category:
Original articles
doi:
https://doi.org/10.33699/PIS.2020.99.4.172–178
Overview
Introduction: Neoadjuvant therapy (NT) applied before breast cancer surgery can lead in favourable cases to regression of the tumor or its total disappearance – pathological complete response (pCR). Due to downstaging after NT, the extent of the surgery can be reduced. pCR represents an important prognostic factor for survival. The aim of this study was to evaluate the effectiveness of NT resulting in pCR on our sample of patients and to assess the frequency of locoregional recurrence (LRR) depending on the extent of the surgery in postoperative care.
Methods: This retrospective study was performed on a sample of 96 patients who underwent breast cancer surgery between 2006 and 2018 after previous NT. On the basis of the histological examination after surgery we evaluated the degree of regression and thus also pCR. In postoperative care we followed the patients for any occurrence of LRR in the breast and axilla.
Results: pCR (Chevallier 1) was observed in 26 cases – 27.1%. During follow-up in postoperative care, 8 cases of LRR occurred – 8.3% (5.2% after mastectomy and 2.1% after breast-conserving surgery). Mean follow-up was almost 30 months with the median of 26.5 months.
Conclusion: With the development of new NT procedures a significant rise in pCR has occurred, predominantly in HER 2+ and triple negative subtypes, thus leading to a decreased incidence of LRR. The number of breast-conserving surgeries with sentinel lymph node biopsy is rising. In a select group of patients breast-conserving surgery is safe and is associated with a low number of LRR events.
Keywords:
breast carcinoma – neoadjuvant therapy – pathological complete response – locoregional recurrence
Sources
- Singletary SE. Neoadjuvant chemotherapy in the treatment of stage II and III breast cancer. Am J Surg. 2001;(182):341−346. doi:10.1016/s0002-9610(01)00724-3.
- Houssami N, Macaskill P, von Minckwitz G, et al. Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy. Eur J Cancer 2012;48(18):3342−3354. doi:10.1016/j.ejca.2012.05.023.
- Gentile LF, Plitas G, Zabor EC, et al. Tumor biology predicts pathologic complete response to neoadjuvant chemotherapy in patients presenting with locally advanced breast cancer. Ann Surg Oncol. 2017;24(13):3896−3902. doi:10.1245/s10434-017-6085-y.
- Chen AM, Meric-Bernstam F, Hunt KK, et al. Conservation after neoadjuvant chemotherapy: The MD Anderson Cancer Center experience. J Clin Oncol. 2004;15;(22):2303−2312. doi:10.1200/JCO.2004.09.062.
- Mamtani A, Barrio AV, King TA, et al. How often does neoadjuvant chemotherapy avoid axillary dissection in patients with histologically confirmed nodal metastases? Results of a prospective study. Ann Surg Oncol. 2016;23(11):3467−3474. doi:10.1245/s10434-016-5246-8.
- Boughey JC, Suman VJ, Mittendorf EA. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. 2013;310(14):1455−1461. doi:10.1001/jama.2013.278932.
- Kuehn T, Bauerfeind I, Fehm T, et al. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol. 2013;(14):609−618. doi: 10.1016/S1470-2045(13)70166-9.
- Moo TA, Edelweiss M, Set H, et al. Is low-volume disease in the sentinel node after neoadjuvant chemotherapy an indication for axillary dissection? Ann Surg Oncol. 2018;(25):1488–1494. doi:10.1245/s10434-018-6429-2.
- Al-Hilli Z, Hoskin TL, Day CN, et al. Impact of neoadjuvant chemotherapy on nodal disease and nodal surgery by tumor subtype. Ann Surg Oncol. 2018;25(2):482−493. doi:10.1245/s10434-017-6263-y.
- van la Parra R, Kuerer HM. Selective elimination of breast cancer surgery in exceptional responders: historical perspective and current trials. Breast Cancer Research 2016;18(1):28. doi:10.1186/s13058-016-0684-6.
- Gentile LF, Plitas G, Zabor EC, et al. Tumor biology predicts pathologic complete response to neoadjuvant chemotherapy in patients presenting with locally advanced breast cancer. Breast Cancer Ann Surg Oncol. 2017;24(13):3896−3902. doi:10.1245/s10434-017-6085-y.
- Coufal O, Fait V a kol. Chirurgická léčba karcinomu prsu. 1 vydání, Praha, Grada 2011.
- Fisher ER, Wang J, Bryant J, et al. Pathobiology of preoperative chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18. Cancer 2002;(15):681−695. doi:10.1002/cncr.10741.
- Akay CL, Meric-Bernstam F, Hunt KK, et al Evaluation of the MD Anderson Prognostic Index for local-regional recurrence after breast conserving therapy in patients receiving neoadjuvant chemotherapy. Ann Surg Oncol. 2012;(19):901−917. doi:10.1245/s10434-011-200.
- Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and long-term survival in patients with triplenegative breast cancer. J Clin Oncol. 2008;26(8):1275−1281. doi:10.1200/JCO.2007.14.4147.
- Gianni L, Pienkowski T, Im YH, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13(1):25−32. doi:10.1016/S1470-2045(11)70336-9.
- Baron P, Beitsch P, Boselli D, et al. Impact of tumor size on probability of pathologic complete response after neoadjuvant chemotherapy. Ann Surg Oncol. 2016;23(5):1522−1529. doi:10.1245/s10434-015-5030-1.
- Curigliano G, Burstein HJ, Winer EP, et al. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann Oncol. 2017;(28):1700−1712. doi:10.1093/annonc/mdx308.
- Balic M, Thomssen CH, Würstlein R, et al. St. Gallen/Vienna 2019: A brief summary of the consensus discussion on the optimal primary breast cancer treatment. Breast Care 2019;(14):103–110. doi:10.1159/000499931.
- Chen AM, Meric-Bernstam F, Hunt KK, et al Breast conservation after neoadjuvant chemotherapy. Cancer 2005;(103):689−695. doi:10.1002/cncr.20815.
- Ataseven B, Lederer B, Blohmer JU, et al. Impact of multifocal or multicentric disease on surgery and locoregional, distant and overall survival of 6,134 breast cancer patients treated with neoadjuvant chemotherapy. Ann Surg Oncol. 2015;22(4):1118−1127. doi:10.1245/s10434-014-4122-7.
- Woods RW, Camp MS, Durr NJ, et al A review of options for localization of axillary lymph nodes in the treatment of invasive breast cancer. Acad Radiol. 2019;(26):805−819. doi:10.1016/j.acra.2018.07.002.
- Caudle AS, Yang WT, Krishnamurthy S, et al. Improved axillary evaluation following neoadjuvant therapy for patients with node-positive breast cancer using selective evaluation of clipped nodes: Implementation of targeted axillary dissection. J Clin Oncol. 2016;(34):1072−178. doi:10.1200/JCO.2015.64.0094.
Labels
Surgery Orthopaedics Trauma surgeryArticle was published in
Perspectives in Surgery
2020 Issue 4
Most read in this issue
- The effects and use of negative pressure wound therapy – a set of case reports
- Pseudomyxoma peritonei (PMP) and its therapy – 20 years’ experience of a single surgical department
- Current possibilities of minimally invasive therapy of oesophageal diverticula.
- Surgical treatment of breast carcinoma after neoadjuvant therapy